Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds
Data ReadoutpositivetBEPositive
AI Analysis
Summary
Cell Stem Cell published research demonstrating that tBE-mediated base editing therapy achieved durable clinical remission and 100% transfusion independence in sickle cell disease and β-thalassemia patients across diverse populations including Chinese, African, and South/Southeast Asian cohorts. The therapy showed consistent safety and efficacy across different genetic backgrounds.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
tBE-mediated base editing therapy achieved durable clinical remission and transfusion independence in sickle cell disease and β-thalassemia patients across Chinese, African, and South/Southeast Asian populations
Importance:8/10
Sentiment:
0.85
base editinggene therapysickle cell diseasebeta-thalassemiaclinical remissiontransfusion independencemulti-population study
Read the original article
Published by PR Newswire Clinical Trials on September 8, 2026 12:00 AM